
キュビシン®による治療を受けられる患者さん・ご家族の方へ
ここでは感染症や治療や薬のことについて、ご説明いたします。
サイトご利用にあたっての注意事項
当サイトはMSD株式会社の医療用医薬品キュビシン®を処方されている患者さんやそのご家族に、適正使用や安全性に関する情報を提供することを目的としています。医学的アドバイスを提供するものではないことをご了承ください。治療上の判断は、医師にご相談ください。
世界各国の拠点(英語) See our worldwide locations and country contact information
「MSDくすりとワクチンの情報一覧」では、MSD株式会社の医療用医薬品、医療機器をご使用の患者さんに対し、医薬品・医療機器を適正にご使用いただくための情報を提供していますが、医学的アドバイスを提供するものではありません。医療に関する判断は、患者さんの特性を考慮し、医師と患者さんとの相談の上で行うものです。治療上の質問は、医師にご相談下さい。なお、このページの情報は日本国内向けに作成されたものであり、日本国内での使用に限定するものです。
上記を理解し、MSDくすりとワクチンの情報一覧を見る
当サイトはMSD株式会社の医療用医薬品キュビシン®を処方されている患者さんやそのご家族に、適正使用や安全性に関する情報を提供することを目的としています。医学的アドバイスを提供するものではないことをご了承ください。治療上の判断は、医師にご相談ください。
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.